Everest Medicines (HKEX 1952.HK), a China-based biopharmaceutical company, announced on Tuesday that it has started operation and successfully conducted trial production runs for the first phase of its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang Province.
The first phase of the project includes an area of 58,000 square metres and required an investment of over RMB900m. It has a set of advanced production facilities constructed to meet global and China GMP standards and has an annual production capacity of 700 million doses of mRNA vaccines.
Rogers Yongqing Luo, Everest Medicines chief executive officer, said: "The COVID-19 pandemic is still raging globally, and the evolving variants bring significant challenges. We are actively advancing the development of mRNA COVID-19 vaccines to better protect people's health and support China's national public policy. The start-up of our mRNA vaccine factory is a key step in our strategic goal of having a complete industrial value chain of research, clinical development, manufacturing and commercialisation. We will continue to develop our clinically-validated mRNA technology platform across a wide range of diseases, such as infectious diseases and cancer, while preparing for commercialisation, and accelerating our path to becoming a fully-integrated biopharmaceutical company."
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Micron Biomedical names new scientific advisor to CEO
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences